

# Rheumatology & ILD Summit

**27 February - 01 March 2026**  
**Porto, Portugal**

[rheumatology-ildsummit.org](http://rheumatology-ildsummit.org)

Scientific Program: Autoimmune Diseases and Pulmonary Fibrosis: Recent Advances

This program is designed for a multi-day symposium, bringing together rheumatologists, pulmonologists, and translational researchers to explore the intersection of systemic autoimmunity and interstitial lung disease (ILD).

**27 February 2026, Friday**

**09:45-10:00** Welcome- *Antonio Marinho, Nevsun İnanç*

**10:00-12:00** Pathophysiology and the Shared Genetic Landscape

*Focus: Understanding why the immune system targets the lung parenchyma.*

**Chair:** *Antonio Marinho, Gülen Hatemi*

**10:00-10:30** **The "Two-Hit" Hypothesis:** How environmental triggers and genetic susceptibility lead to Autoimmune ILD- *Alper Sari*

**10:30-11:00** **Beyond the Joint:** New insights into the lung as the primary site of autoimmune initiation in Rheumatoid Arthritis (RA)- *Mehmet Engin Tezcan*

**11:00-11:30** Biomarkers for predicting the occurrence and progression of ILD - *Berkan Armağan*

**11:30-12:00** Mechanisms of fibrosis: different pathways in different organs- *Murat İnanç*

**12:00-13:30** Lunch Break

**13:30-14:30** **The Microbiome Link:** How the lung-gut axis influences systemic immune activation and pulmonary scarring

**Chair:** *Sedat Kiraz, Pedro Leuchner*

- Lung axis- *Agostinho Rodrigues Carvalho*
- Gut axis- *Daniel Oliveira*

# Rheumatology & ILD Summit

**27 February - 01 March 2026**  
**Porto, Portugal**

[rheumatology-ildsummit.org](http://rheumatology-ildsummit.org)

**14:30-15:00 Coffee Break**

**15:00-16:30 Panel Discussion:** Redefining "IPAF" (Interstitial Pneumonia with Autoimmune Features) – Are we closer to a formal diagnosis?

**Chair:** *Süleyman Serdar Koca, Raquel Faria*

Cases- *Sinem Nihal Esatoğlu*

Rheumatologic Approach- *Ediz Dalkılıç*

Pulmonology Approach- *Özlem Özdemir Kumbasar*

**28 February 2026, Saturday**

**Emerging Biomarkers and Diagnostic Precision**

*Focus: Improving early detection and predicting disease progression.*

**Serological Breakthroughs**

**Chair:** *Serdal Uğurlu, Carlos Vasconcelos*

**09:00-09:30** Utilizing novel myositis-specific antibodies (MSAs) to predict rapidly progressive ILD- *Gökçe Kenar Artım*

**09:30-10:00** MCTD & Anti-U1RNP: Why 40% of U1RNP-positive patients develop ILD and the significance of the NSIP (Non-Specific Interstitial Pneumonia) pattern- *Sibel Bakırçı*

**10:00-10:30** The Sjögren's-ILD Phenotype: Beyond "Sicca"—Identifying Anti-Ro52 as a high-risk marker for progressive fibrosis- *Ivone Valadão*

# Rheumatology & ILD Summit

**27 February - 01 March 2026**  
**Porto, Portugal**

[rheumatology-ildsummit.org](http://rheumatology-ildsummit.org)

**10:30-11:00 Coffee Break**

**Chair: *Nuno Cortesão, Nevsun İnanç***

11:00-11:30 Using the lung Ultrasound to quantify pulmonary severity- ***Gökhan Sargin***

11:30-12:00 **AI in Radiology:** Leveraging machine learning for the early quantification of subclinical fibrosis- ***Mustafa Erdogan***

**12:00-13:30 Lunch Break**

**Chair: *Mário Santos, Murat İnanç***

**13:30-14:30 Pulmonary Arterial Hypertension (PAH):**

13:30-14:00 Beyond parenchymal disease—Managing the lethal combination of ILD and vascular remodeling in Systemic Sclerosis- ***Ali Akdoğan***

14:00-14:30 Can we differentiate PAH from PH related with ILD- ***Nesrin Moğulkoç***

**14:30-15:00 Coffee Break**

**Chair: *Yavuz Pehlivan, Inês Furtado***

15:00-16:00 **Workshop 1:** Interpreting HRCT Patterns: Identifying UIP vs. NSIP in the autoimmune patient- ***Derya Kocakaya, Göksel AltuŞık Ergür***

16:00-17:30 **Workshop 2:** Basic lung echography workshop- ***Nuno Cortesão***

# Rheumatology & ILD Summit

**27 February - 01 March 2026**  
**Porto, Portugal**

[rheumatology-ildsummit.org](http://rheumatology-ildsummit.org)

**01 March 2026, Sunday**

## **The New Therapeutic Era**

*Focus: Moving from traditional immunosuppression to "Niche" and "Combination" therapies.*

**09:30-10:30 Targeted Biologics**

**Chair: Cemal Bes, Isabel Almeida**

09:30-10:00 Treatment strategies for RA-related interstitial lung disease- **Ender Terzioğlu**

10:00-10:30 The emergence of JAK inhibitors for refractory Dermatomyositis-ILD- **Ana Campar**

**10:30-11:00 Coffee Break**

**Chair: Nesrin Moğulkoç, Antonio Marinho**

11:00-11:30 **Is there room for MTX in ILD treatment:** Recent data (including the PULMORA trial)- **Ivo Barreiro**

**11:30-12:30 Future Frontiers:**

11:30-12:00 Antifibrotic Strategies in ILD: Current Evidence and Future Perspectives- **Sehnaz Yıldızeli**

12:00-12:30 Precision Medicine—Tailoring therapy based on molecular endotypes rather than clinical labels- **José Delgado Alves**

Closing remarks: **Nevsun İnanç, Antonio Marinho**